OptimizeRx Full Year 2022 Earnings: EPS Beats Expectations, Revenues Lag

OptimizeRx (NASDAQ:OPRX) Full Year 2022 Results

Key Financial Results

• Revenue: US$62.5m (up 1.9% from FY 2021).
• Net loss: US$11.4m (down from US$378.1k profit in FY 2021).
• US$0.64 loss per share (down from US$0.022 profit in FY 2021).

All figures shown in the chart above are for the trailing 12 month (TTM) period

OptimizeRx EPS Beats Expectations, Revenues Fall Short

Revenue missed analyst estimates by 3.3%. Earnings per share (EPS) exceeded analyst estimates by 2.7%.

Looking ahead, revenue is forecast to grow 11% p.a. on average during the next 3 years, compared to a 12% growth forecast for the Healthcare Services industry in the US.

Performance of the American Healthcare Services industry.

The company's shares are down 22% from a week ago.

Risk Analysis

Before you take the next step you should know about the 2 warning signs for OptimizeRx (1 can't be ignored!) that we have uncovered.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.